| Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO) T Valentin, A Le Cesne, I Ray-Coquard, A Italiano, G Decanter, E Bompas, ... European journal of cancer 56, 77-84, 2016 | 147 | 2016 |
| Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial A Le Cesne, JY Blay, J Domont, E Tresch-Bruneel, C Chevreau, ... The Lancet Oncology 16 (3), 312-319, 2015 | 107 | 2015 |
| Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) T Valentin, C Fournier, N Penel, E Bompas, L Chaigneau, N Isambert, ... Investigational new drugs 31, 1626-1627, 2013 | 62 | 2013 |
| Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK (+) cell growth C Hoareau-Aveilla, T Valentin, C Daugrois, C Quelen, G Mitou, S Quentin, ... The Journal of clinical investigation 125 (9), 3505-3518, 2015 | 43 | 2015 |
| Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma A Dufresne, T Lesluyes, C Ménétrier-Caux, M Brahmi, E Darbo, ... Oncoimmunology 9 (1), 1792036, 2020 | 41 | 2020 |
| Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas S Le Guellec, T Lesluyes, E Sarot, C Valle, T Filleron, P Rochaix, ... Annals of Oncology 29 (8), 1828-1835, 2018 | 37 | 2018 |
| Surgical margins and adjuvant therapies in malignant phyllodes tumors of the breast: a multicenter retrospective study M Neron, C Sajous, S Thezenas, S Piperno-Neumann, F Reyal, M Laé, ... Annals of surgical oncology 27, 1818-1827, 2020 | 35 | 2020 |
| VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients. J Geriatr Oncol S1879-4068 (21) 00015-1 L Mourey, F Le Louedec, A Ravaud, MN Paludetto, L Digue, ... | 33 | 2021 |
| CINSARC signature as a prognostic marker for clinical outcome in sarcomas and beyond F Chibon, T Lesluyes, T Valentin, S Le Guellec Genes, Chromosomes and Cancer 58 (2), 124-129, 2019 | 31 | 2019 |
| Brain metastases from adult sarcoma: prognostic factors and impact of treatment. A retrospective analysis from the French Sarcoma Group (GSF/GETO) L Chaigneau, A Patrikidou, I Ray‐Coquard, T Valentin, C Linassier, ... The Oncologist 23 (8), 948-955, 2018 | 24 | 2018 |
| First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors E Elez, C Gomez-Roca, A Soto Matos-Pita, G Argiles, T Valentin, ... Investigational New Drugs 37, 674-683, 2019 | 20 | 2019 |
| Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA) A Patrikidou, L Chaigneau, N Isambert, K Kitikidou, R Shanley, ... BMC cancer 20, 1-11, 2020 | 14 | 2020 |
| Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas M Brahmi, T Lesluyes, A Dufresne, M Toulmonde, A Italiano, O Mir, ... ESMO open 6 (1), 100037, 2021 | 13 | 2021 |
| Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial JY Blay, S Chevret, A Le Cesne, M Brahmi, N Penel, S Cousin, F Bertucci, ... The Lancet Oncology 24 (8), 892-902, 2023 | 12 | 2023 |
| Evaluation of eight melanocytic and neural crest‐associated markers in a well‐characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to … M Gaspard, L Lamant, E Tournier, T Valentin, P Rochaix, P Terrier, ... Histopathology 73 (6), 969-982, 2018 | 12 | 2018 |
| Chemotherapy in localized soft tissue sarcoma: will we soon have to treat grade 1 tumors? Update on CINSARC performances T Valentin, T Lesluyes, S Le Guellec, F Chibon Annals of Oncology 30 (1), 153-155, 2019 | 11 | 2019 |
| Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group M Brahmi, N Gaspar, J Gantzer, M Toulmonde, P Boudou‐Rouquette, ... Cancer Medicine 12 (7), 7801-7807, 2023 | 9 | 2023 |
| Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial T Filleron, S Le Guellec, C Chevreau, B Cabarrou, T Lesluyes, S Lodin, ... BMC cancer 20, 1-8, 2020 | 9 | 2020 |
| Outcome of 91 clear cell sarcoma tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO). N Firmin, P Boudou-Rouquette, D Duliege, L Chaltiel, SN Dumont, ... Journal of Clinical Oncology 36 (15_suppl), 11552-11552, 2018 | 5 | 2018 |
| Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with … A Le Cesne, JY Blay, T Ryckewaert, C Chevreau, F Bertucci, ... Journal of Clinical Oncology 32 (15_suppl), 10523-10523, 2014 | 5 | 2014 |
